AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01076868
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine x 14 days
Trial: NCT00918164
Drug: PF-04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, 8 mg as oral tablet and solution formulation
Trial: NCT02086487
Drug: Nilotinib 300 mg.
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)
Trial: NCT02324166
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cephalosporin antibiotic
Trial: NCT02324166
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthetic
Trial: NCT03070171
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01126437
Drug: tiotropium 18 mcg
RxNorm normalized name: tiotropium 18 MCG Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HandiHaler
Trial: NCT01126437
Drug: tiotropium 1.25 mcg (2 actuations/day)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft mist inhaler 2 actuations=2 puffs/day
Trial: NCT01126437
Drug: tiotropium 2.5 mcg (2 actuations/day)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft mist inhaler (2 actuations=2 puffs/day)
Trial: NCT03737448
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with receive up to 60 mg daily
Trial: NCT00615589
Drug: Fludarabine/Busulfan x 4 days
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day.
Trial: NCT05474781
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HCV treatment
Trial: NCT04493541
Drug: BMS-986256
RxNorm normalized name: BMS-986256
DrugBank: Afimetoran (DB16580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT02851797
Drug: givinostat
RxNorm normalized name: givinostat
DrugBank: Givinostat (DB12645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid
Trial: NCT02182024
Drug: Dabigatran etexilate high dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182024
Drug: Dabigatran etexilate low dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04361409
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/m2 on Day-14 and Day-7
Trial: NCT04361409
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg/m2 on Day1
Trial: NCT04361409
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 on Day8
Trial: NCT02727296
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia with sevoflurane
Trial: NCT02727296
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia with propofol
Trial: NCT01906385
Drug: Rhenium Liposome Treatment
RxNorm normalized name: rhenium
DrugBank: Rhenium re-186 (DB19266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
Trial: NCT02843035
Drug: venglustat (GZ402671)
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule or tablet~Route of administration: oral
Trial: NCT02843035
Drug: imiglucerase
RxNorm normalized name: Imiglucerase
DrugBank: Imiglucerase (DB00053)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous
Trial: NCT04195555
Drug: Ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03628066
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg by mouth daily for 24 weeks
Trial: NCT03628066
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
Trial: NCT03628066
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
Trial: NCT00442533
Drug: Indium-111 pentetreotide
RxNorm normalized name: Indium-111 Pentetreotide
DrugBank: Indium-111 Pentetreotide (DB17335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of 500 mCi treatments every 10-12 weeks
Trial: NCT00177294
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
Trial: NCT03013387
Drug: Amino Acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
Trial: NCT02110355
Drug: AMG 232
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as an oral tablet in escalating doses
Trial: NCT02110355
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib is an anti-cancer agent
Trial: NCT02110355
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib is an anti-cancer agent
Trial: NCT03208660
Drug: Fycompa
RxNorm normalized name: FYCOMPA
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral suspension
Trial: NCT00799227
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
Trial: NCT02775591
Drug: DA-9701
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-9701 30mg Tablet
Trial: NCT00391430
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
Trial: NCT02959853
Drug: Anastrazole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03069248
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03069248
Drug: Alpha Interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04958993
Drug: Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
RxNorm normalized name: ephedrine hydrochloride Oral Tablet [Primatene with ephedrine]
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
Trial: NCT02483156
Drug: Sofosbuvir tablet (SOF) 400 mg - once daily
RxNorm normalized name: eslicarbazepine
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
Trial: NCT02483156
Drug: Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening
RxNorm normalized name: Pyrrolid-2-one
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
Trial: NCT00061815
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 IV
Trial: NCT00061815
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV
Trial: NCT00061815
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV
Trial: NCT00426400
Drug: The cessation of anti-aggregative treatment for 10 days
RxNorm normalized name: Extract of the Sterile Caules of Equisetum Arvense
DrugBank: Equisetum arvense top (DB14349)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01453205
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Trial: NCT01453205
Drug: ICE
RxNorm normalized name: Ice
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
Trial: NCT01453205
Drug: DHAP
RxNorm normalized name: DHAP
DrugBank: Dihydroxyacetone phosphate (DB04326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Trial: NCT01618760
Drug: Risperidone Tablet 1 mg
RxNorm normalized name: risperidone Oral Tablet
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg tablet once a day
Trial: NCT00503581
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orally
Trial: NCT01618760
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg tablet once a day
Trial: NCT02153502
Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
RxNorm normalized name: D6-dextromethorphan
DrugBank: Deudextromethorphan (DB19054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP-786 capsules administered twice a day over a 10-week period
Trial: NCT02680782
Drug: X4P-001
RxNorm normalized name: CXCR4 INHIBITOR X4P-001
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
Trial: NCT02662283
Drug: Reh-acteoside
RxNorm normalized name: ascorbyl lactoside
DrugBank: Acteoside (DB12996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral take and reh-acteoside (0.4g bid) for 8 weeks
Trial: NCT02407340
Drug: oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
Trial: NCT01996696
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg PO TID x 30-36 months
Trial: NCT00467194
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00467194
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00722722
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Velcade given in four-dose cycles intravenously (through a vein).
Trial: NCT03475706
Drug: Solabegron immediate release tablets, low dose
DrugBank: Solabegron (DB06190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 12 weeks.
Trial: NCT03475706
Drug: Solabegron immediate release tablets, high dose
DrugBank: Solabegron (DB06190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 12 weeks.
Trial: NCT04294498
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
Trial: NCT02682680
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.75 g daily for 24 weeks
Trial: NCT02682680
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10 mg daily for 24 weeks
Trial: NCT05206448
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole tablet
Trial: NCT05206448
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate tablet
Trial: NCT02320435
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
Trial: NCT02320435
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Trial: NCT02650804
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01573910
Drug: Ofloxacin ophthalmic solution, 0.3%
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02633163
Drug: Low Dose Mesenchymal Stem Cells (MSCs)
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
Trial: NCT02633163
Drug: High Dose Mesenchymal Stem Cells (MSCs)
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution.
Trial: NCT04165070
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04165070
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04165070
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT02251912
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
Trial: NCT03504202
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .
Trial: NCT03513770
Drug: ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
Trial: NCT03513770
Drug: saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
Trial: NCT03409874
Drug: NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
Trial: NCT01558362
Drug: 123I-CMICE-013
RxNorm normalized name: 123I-
DrugBank: 123I-iodometomidate (DB13021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections. All volunteers had a rest dose first followed by a stress dose.
Trial: NCT04497519
Drug: inhaled hydroxychloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascending dose of iHCQ
Trial: NCT03611699
Drug: Umeclidinium / Vilanterol Dry Powder Inhaler
RxNorm normalized name: umeclidinium / vilanterol Dry Powder Inhaler
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: umeclidinium/vilanterol dry powder inhaler
Trial: NCT02054182
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
Trial: NCT03585764
Drug: MOv19-BBz CAR T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.